Company officials say its proprietary Tumor Treating Fields technology, marketed under the product name Optune, are a new tool in the war against cancer. Currently, the company has FDA approval for Glioblastoma, the deadliest form of brain cancer.
The results thus far have been impressive for Novocure. In December, data from the company’s pivotal phase 3 trial of its Optune device, published in the Journal of the American Medical Association, showed that Optune along with temozolomide chemotherapy significantly extended progression-free survival and overall survival compared to temozolomide alone in treating newly diagnosed glioblastoma.
MassDevice publisher Brian Johnson recently caught up with Bill Doyle, chairman, NovoCure to discuss the technology, the company’s origins and how its current concentration on glioblastoma is just the beginning for the company.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!